Vitality Biopharma Inc (OTCMKTS:VBIO)
Vitality Biopharma Inc(OTCMKTS:VBIO), headquartered in Los Angeles, CA, is developing a specific class of ingestible cannabinoid prodrugs, known as cannabosides, to provide therapeutic benefits without the THC inducing psychoactive side-effects that may limit dosage. A prodrug is a medication or compound that, after administration, is metabolized into a pharmacologically active drug. Interestingly, Vitality states there have been approximately 15 prodrugs that have been classified as blockbusters, which is defined as having achieved annual sales exceeding $1 billion.
Vitality Biopharma Inc (OTCMKTS:VBIO) claims that independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease (IBD) patients experience symptomatic relief, including 84% of patients who report improvement in visceral or abdominal pain. Approximately 1.4 million Americans have IBD, including Crohn’s disease and ulcerative colitis.
A proprietary glycosylation platform has been developed by Vitality Biopharma Inc (OTCMKTS:VBIO). The result is that they are able to produce and characterize more than 20 novel cannabinoid glycosides, or “cannabosides”. These drug candidates represent a new class of cannabinoid pharmaceuticals. It is well established that cannabis can provide relief of pain and inflammation in certain disease indications. Vitality Biopharma claims their prodrugs could exert the same beneficial therapeutic effects, but with improvements such as targeted drug delivery that avoids or reduces psychoactivity. Vitality Biopharma Inc (OTCMKTS:VBIO) believes that targeted delivery through glycosylation may enable selective delivery of compounds to the brain or digestive tract and improve the safety and efficacy of existing drugs.
Vitality Biopharma Inc (OTCMKTS:VBIO) has filed intellectual property applications and is seeking worldwide patent protection through 2035 for prodrugs of THC, CBD, and CBDV, as well as for its proprietary prodrug biosynthesis platform utilizing enzymatic glycosylation.
Last week, Vitality Biopharma Inc (OTCMKTS:VBIO) announced the release of a clinical report detailing the ability of cannabinoid therapy to induce remission in a pediatric inflammatory bowel disease patient. The report describes how a specific patient’s disease could not be controlled by currently-approved pharmaceuticals, and how cannabinoid treatment led to near-immediate clinical improvement that was indicative of disease remission.
Shares of Vitality Biopharma Inc (OTCMKTS:VBIO) are up over 25% since the company released the report.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.